Andrew A. Wilson, MD

Associate Professor, Medicine

Andrew Wilson
617.638.4860
72 E. Concord St Housman (R)

Biography

I am a pulmonary and critical care clinician-scientist with a long-standing focus on regenerative medicine and stem cell biology. My goal is to advance understanding of and treatment for genetic causes of chronic obstructive pulmonary disease (COPD) and the most common genetic cause of COPD, alpha-1 antitrypsin deficiency (AATD). To accomplish this goal, I have established an integrated clinical and research program here at BU and BMC that includes the following components: 1) The Alpha-1 Center which I direct and co-founded with Dr. Darrell Kotton has become a nationally recognized center of excellence for the care of AATD patients and their families; 2) Patient stem cell repositories: I have overseen the creation of and direct two large stem cell repositories, housed at the CReM. First, we house the world’s largest AATD patient-specific induced pluripotent stem cell (iPSC) repository, comprised of iPSCs and reprogrammable blood samples from over 100 AATD patients linked to phenotypic data including imaging, pulmonary function, and liver biopsy results. Second, in collaboration with the Framingham Heart Study (FHS) and Vasan Ramachandran, the CReM now houses the FHS iPSC Repository that includes iPSCs and reprogrammable blood samples from >6500 highly phenotyped participants in the FHS; 3) Clinical-epidemological AATD Research: Under my direction as site PI, BU is one three sites in the country funded by the Alpha-1 Foundation to recruit 100 AATD subjects to undergo liver biopsy, detailed phenotyping, and 5 years of follow-up to define the prevalence of, risk factors for, and non-invasive biomarkers associated with AATD-associated liver disease; 4) Translational bench research: my lab in the CReM is focused on the application of patient-derived iPSCs to study AATD and COPD.

The 4 core areas of my research are: I) to confirm the clinical significance of the iPSC platform to model in vivo patient biology and demonstrate its potential for testing potential therapeutic agents; II) to better understand the genetic factors and mechanistic drivers that predispose subsets of AATD patients to develop clinical disease; III) to elucidate the mechanistic contribution of putative COPD susceptibility genes to lung disease pathogenesis; and IV) to develop gene or cell-based therapies for AATD.

Research interests include:
-Alpha-1 antitrypsin deficiency
-COPD pathogenesis
-Gene therapy
-Pluripotent stem cells

Clinical interests include:
-Alpha-1 antitrypsin deficiency

Other Positions

  • Active Staff Privileges, Pulmonary, Allergy, Sleep & Critical Care Medicine, Medicine, Boston Medical Center

Education

  • University of Texas Southwestern Medical School, MD
  • Williams College, BA

Publications

  • Published on 2/22/2019

    Reeves EP, Dunlea DM, McQuillan K, O'Dwyer CA, Carroll TP, Saldova R, Akepati PR, Wormald MR, McElvaney OJ, Shutchaidat V, Henry M, Meleady P, Keenan J, Liberti DC, Kotton DN, Rudd PM, Wilson AA, McElvaney NG. Circulating Truncated Alpha-1 Antitrypsin Glycoprotein in Patient Plasma Retains Anti-Inflammatory Capacity. J Immunol. 2019 Apr 15; 202(8):2240-2253. PMID: 30796179.

    Read at: PubMed
  • Published on 10/15/2018

    Reeves EP, O'Dwyer CA, Dunlea DM, Wormald MR, Hawkins P, Alfares M, Kotton DN, Rowe SM, Wilson AA, McElvaney NG. Ataluren, a New Therapeutic for Alpha-1 Antitrypsin-Deficient Individuals with Nonsense Mutations. Am J Respir Crit Care Med. 2018 10 15; 198(8):1099-1102. PMID: 30011228.

    Read at: PubMed
  • Published on 9/15/2018

    Kaserman JE, Wilson AA. Patient-Derived Induced Pluripotent Stem Cells for Alpha-1 Antitrypsin Deficiency Disease Modeling and Therapeutic Discovery. Chronic Obstr Pulm Dis. 2018 Sep 15; 5(4):258-266. PMID: 30723783.

    Read at: PubMed
  • Published on 7/21/2018

    Giadone RM, Rosarda JD, Akepati PR, Thomas AC, Boldbaatar B, James MF, Wilson AA, Sanchorawala V, Connors LH, Berk JL, Wiseman RL, Murphy GJ. A library of ATTR amyloidosis patient-specific induced pluripotent stem cells for disease modelling and in vitro testing of novel therapeutics. Amyloid. 2018 Sep; 25(3):148-155. PMID: 30032658.

    Read at: PubMed
  • Published on 6/5/2018

    Segeritz CP, Rashid ST, de Brito MC, Serra MP, Ordonez A, Morell CM, Kaserman JE, Madrigal P, Hannan NRF, Gatto L, Tan L, Wilson AA, Lilley K, Marciniak SJ, Gooptu B, Lomas DA, Vallier L. hiPSC hepatocyte model demonstrates the role of unfolded protein response and inflammatory networks in a1-antitrypsin deficiency. J Hepatol. 2018 Oct; 69(4):851-860. PMID: 29879455.

    Read at: PubMed
  • Published on 8/15/2017

    Coleman FT, Blahna MT, Kamata H, Yamamoto K, Zabinski MC, Kramnik I, Wilson AA, Kotton DN, Quinton LJ, Jones MR, Pelton SI, Mizgerd JP. Capacity of Pneumococci to Activate Macrophage Nuclear Factor ?B: Influence on Necroptosis and Pneumonia Severity. J Infect Dis. 2017 Aug 15; 216(4):425-435. PMID: 28368460.

    Read at: PubMed
  • Published on 4/10/2017

    Pastore N, Attanasio S, Granese B, Castello R, Teckman J, Wilson AA, Ballabio A, Brunetti-Pierri N. Activation of the c-Jun N-terminal kinase pathway aggravates proteotoxicity of hepatic mutant Z alpha1-antitrypsin. Hepatology. 2017 Jun; 65(6):1865-1874. PMID: 28073160.

    Read at: PubMed
  • Published on 1/1/2017

    Kaserman JE, Wilson AA. Protocol for Directed Differentiation of Human Induced Pluripotent Stem Cells (iPSCs) to a Hepatic Lineage. Methods Mol Biol. 2017; 1639:151-160. PMID: 28752455.

    Read at: PubMed
  • Published on 6/29/2016

    Payne JG, Takahashi A, Higgins MI, Porter EL, Suki B, Balazs A, Wilson AA. Multilineage transduction of resident lung cells in vivo by AAV2/8 for a1-antitrypsin gene therapy. Mol Ther Methods Clin Dev. 2016; 3:16042. PMID: 27408904.

    Read at: PubMed
  • Published on 4/13/2015

    Tafaleng EN, Chakraborty S, Han B, Hale P, Wu W, Soto-Gutierrez A, Feghali-Bostwick CA, Wilson AA, Kotton DN, Nagaya M, Strom SC, Roy-Chowdhury J, Stolz DB, Perlmutter DH, Fox IJ. Induced pluripotent stem cells model personalized variations in liver disease resulting from a1-antitrypsin deficiency. Hepatology. 2015 Jul; 62(1):147-57. PMID: 25690322.

    Read at: PubMed

View 10 more publications: View full profile at BUMC

View all profiles